Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia

The development of different generations of BCR-ABL1 tyrosine kinase inhibitors (TKIs) has led to the high overall survival of chronic myeloid leukemia (CML) patients. However, there are CML patients who show resistance to TKI therapy and are prone to progress to more advanced phases of the disease....

Descripción completa

Detalles Bibliográficos
Autores principales: Houshmand, Mohammad, Vitale, Nicoletta, Orso, Francesca, Cignetti, Alessandro, Molineris, Ivan, Gaidano, Valentina, Sainas, Stefano, Giorgis, Marta, Boschi, Donatella, Fava, Carmen, Passoni, Alice, Gai, Marta, Geuna, Massimo, Sora, Federica, Iurlo, Alessandra, Abruzzese, Elisabetta, Breccia, Massimo, Mulas, Olga, Caocci, Giovanni, Castagnetti, Fausto, Taverna, Daniela, Oliviero, Salvatore, Pane, Fabrizio, Lolli, Marco Lucio, Circosta, Paola, Saglio, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247109/
https://www.ncbi.nlm.nih.gov/pubmed/35773274
http://dx.doi.org/10.1038/s41419-022-05028-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247109/
https://www.ncbi.nlm.nih.gov/pubmed/35773274
http://dx.doi.org/10.1038/s41419-022-05028-9

Ejemplares similares